Men & Women
Longevity SGLT2
The geroscience drug class Barzilai ranks #1.
Status
Waitlist
Class
SGLT2 inhibitor
Evidence
Tier 1
Medications
3
About this stack
SGLT2 inhibitors were developed for type 2 diabetes but have shown stunning cardiovascular and renal outcomes in trials independent of glucose control. Nir Barzilai, director of the Institute for Aging Research, has called SGLT2 inhibitors the most promising geroprotective drug class. This stack adds acarbose (glucose spike reduction) and pharmaceutical-grade magnesium for metabolic completeness.
The science
The DAPA-HF and EMPEROR-Reduced trials showed dapagliflozin reduced hospitalization for heart failure and cardiovascular death in patients with and without diabetes. Emerging geroscience data suggests SGLT2 inhibition may extend healthspan via mechanisms beyond glucose — including reduced inflammation and mitochondrial optimization.
Common questions
Why is this on a waitlist?
We're finalizing pharmacy sourcing and clinical protocol. We expect to launch this stack in the coming months. Join the waitlist to be notified at launch.
Why does Barzilai rank SGLT2s so highly?
SGLT2 inhibitors have shown robust real-world cardiovascular and renal benefits in multiple large trials — benefits that appear independent of their glucose-lowering mechanism, suggesting a broader geroprotective effect.
Can I take this with Longevity Base?
Yes. SGLT2 and rapamycin/metformin operate via distinct mechanisms. Combination use is being studied and is common in longevity-focused practices.
Longevity SGLT2 — Coming Soon
We're finalizing pharmacy sourcing. Join the waitlist to be notified at launch.
Join Waitlist